Lupin Share Price
52 Week Range
- Open Price
- Previous Close
Start SIP in LUPINStart SIP
Lupin Investment Rating
Lupin (Nse) has an operating revenue of Rs. 15,879.13 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of -8% needs improvement, ROE of -12% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 7 which is a FAIR score but needs to improve its earnings, a RS Rating of 18 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
|Indicator||Jun 2022||Mar 2022||Dec 2021||Sep 2021||Jun 2021||Mar 2021|
|Oper Rev Qtr Cr||2,684||2,504||2,663||2,799||3,314||2,516|
|Operating Expenses Qtr Cr||2,444||2,354||2,524||4,269||2,349||2,091|
|Operating Profit Qtr Cr||289||501||208||-1,399||965||425|
|Depreciation Qtr Cr||130||131||128||130||125||125|
|Interest Qtr Cr||20||25||16||18||15||12|
|Tax Qtr Cr||28||397||-430||-143||204||37|
|Net Profit Qtr Cr||117||-36||530||-1,329||646||316|
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Lupin Resistance and Support
|MACD Single Line||-1|
Lupin Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Lupin Result Highlights
NSE-Medical-Generic DrugsLupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11771.67 Cr. and Equity Capital is Rs. 90.90 Cr. for the Year ended 31/03/2022. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
|Shares in Float||24.10|
|No of funds||557|
|U/D Vol ratio||1.3|
|LTDebt / Equity|
|Foreign Portfolio Investors||14.27%||14.65%||15.28%|
|Financial Institutions/ Banks||0.14%||0.14%||0.14%|
|Mrs. Manju D Gupta||Chairman|
|Dr. Kamal K Sharma||Vice Chairman|
|Mr. Nilesh D Gupta||Managing Director|
|Ms. Vinita Gupta||Executive Director & CEO|
|Mr. Ramesh Swaminathan||Executive Director & Global CFO|
|Mr. Jean-Luc Belingard||Independent Director|
|Ms. Christine Mundkur||Independent Director|
|Mr. K B S Anand||Independent Director|
|Dr. Punita Kumar-Sinha||Independent Director|
|Mr. Mark D McDade||Independent Director|
Lupin Corporate Action
|2022-05-18||Audited Results & Final Dividend|
|2022-07-15||FINAL||Rs.4.00 per share(200%)Final Dividend|
|2021-07-28||FINAL||Rs.6.50 per share(325%)Final Dividend|
What is Share Price of Lupin ?
Lupin share price is ₹654 As on 30 September, 2022 | 01:44
What is the Market Cap of Lupin ?
The Market Cap of Lupin is ₹29772.1 Cr As on 30 September, 2022 | 01:44
What is the P/E ratio of Lupin ?
The P/E ratio of Lupin is -13.8 As on 30 September, 2022 | 01:44
What is the PB ratio of Lupin ?
The PB ratio of Lupin is 2.4 As on 30 September, 2022 | 01:44
What were the company's reported sales and net income in 2022?
For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.
What is the future of Lupin Limited's shares?
Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.